Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024

Journey Medical Corp

2024-Q1 EPS reported -$0.53 revenue$13,030,000

Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.
Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.
R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.
SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.
FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.

Period: first quarter ended March 31, 2024
Revenue: Total net product revenues were $13.0 million
Net income: Net loss was $10.4 million
EPS: $(0.53) per share basic and diluted
Result: reported results

Exact text from the filing

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-060513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.